Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Marker for predicting response of esophageal adenocarcinoma patient to combined treatment and application thereof

A combined therapy, esophageal adenocarcinoma technology, applied in the field of biomedicine, can solve the problems of high treatment-related mortality and adverse reaction incidence

Inactive Publication Date: 2022-02-08
QINGDAO MEDINTELL BIOMEDICAL CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, considering the high treatment-related mortality rate, adverse reaction rate, and decreased quality of life caused by esophagectomy, whether patients with pCR after NCRT can be postponed or exempted from surgery is increasingly attracting researchers' attention. Hot Discussion and Concern

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Marker for predicting response of esophageal adenocarcinoma patient to combined treatment and application thereof
  • Marker for predicting response of esophageal adenocarcinoma patient to combined treatment and application thereof
  • Marker for predicting response of esophageal adenocarcinoma patient to combined treatment and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0068] Example 1. Screening molecular markers and verifying their predictive effects

[0069] The data source for this study is: GSE165252. In patients with resectable esophageal adenocarcinoma Figure 4 Prior to the indicated combination therapy, patient tumor biopsy samples were collected for RNA-sequencing. After the patients received the treatment, according to whether the patients responded to the combination therapy, the patients were divided into a response group (R, responder) or a non-response group (NR, non-responder), and the gene expressions of the response group patients and the non-response group patients were compared Spectrum, potentially predictive markers for response to combination therapy. The "combination therapy" mentioned above refers to the combination of neoadjuvant chemoradiotherapy and atezolizumab therapy. Non-responder in this data set: responder=20:12. Differential analysis was carried out with the limma package of R language, and screening w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biomedicine, and particularly relates to a marker for predicting response of an esophageal adenocarcinoma patient to combined treatment and application thereof. The combined treatment provided by the invention is neoadjuvant radiotherapy and chemotherapy combined with attezumab treatment. In particular, the marker includes RORB, IGKV19, FGD5P1, or a combination thereof.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to a marker for predicting response of patients with esophageal adenocarcinoma to combined therapy and application thereof. Background technique [0002] Esophageal cancer is a common digestive tract tumor, and about 300,000 people worldwide die from esophageal cancer every year. Its morbidity and mortality vary widely from country to country. The incidence of esophageal cancer ranks third among malignant tumors in China, and the death rate ranks fourth. The 5-year survival rate of patients with limited advanced stage is only 24%. When most patients are diagnosed, they are already in the middle and late stage, and the survival rate is low. The typical symptom of esophageal cancer is progressive dysphagia, first it is difficult to swallow dry food, then semi-liquid food, and finally water and saliva cannot be swallowed. The population distribution of esophageal cancer is rel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886G01N33/577G01N33/574
CPCC12Q1/6886G01N33/577G01N33/57484G01N33/57488G01N33/57407C12Q2600/106C12Q2600/158G01N2800/52G01N2800/60
Inventor 杨承刚郭静
Owner QINGDAO MEDINTELL BIOMEDICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com